The United States currently drives approximately 46% of global oncology expenditures, reflecting a rapid influx of nearly 150 new active substances approved between 2015 and 2024. This momentum is increasingly focused on gastrointestinal malignancies, where recent regulatory milestones—including the first broad RAS-targeted therapy for metastatic pancreatic cancer—have shifted long-standing treatment paradigms.
In section Releases
Oncology Market Surge: Drug Spending Poised to Top $400 Billion
Global spending on cancer therapeutics is projected to climb past $400 billion by 2028, fueled by an accelerated pipeline of new treatments. As the industry pivots toward historically difficult targets like pancreatic and colorectal cancers, clinical trial activity has surged nearly 40% over the last five-year window.
Companies are aggressively addressing previously "undruggable" mutations. Oncolytics Biotech is advancing pelareorep to enhance immune visibility in colorectal tumors, while Revolution Medicines recently secured FDA approval for RASONQUE, demonstrating improved survival rates in pancreatic cancer patients. Meanwhile, Eli Lilly and Genmab have reported significant trial successes in lymphoma and leukemia, further expanding the current standard of care. Investors are now turning their attention to the upcoming European Society for Medical Oncology Congress in Madrid, where new data on these complex tumor profiles will likely dictate the next phase of market development.
Comments (0)
No comments yet. Be the first!